Senior pharmaceutical executive and transformation leader with a strong track record of accelerating global regulatory and data-driven submissions across therapeutic areas. Combines deep expertise in regulatory science, digital standards, and enterprise operating models to deliver measurable improvements in speed, quality, and compliance. Led complex, cross-functional transformations spanning CMC, clinical, Patient Safety, and labeling, achieving significant cycle-time reductions (including >180-day acceleration in CSR delivery). Known for designing scalable governance, data strategies, and submission frameworks aligned to emerging standards such as IDMP, PQ/CMC, and eCTD 4.0.
Trusted advisor to senior leadership and regulators, with direct engagement with the U.S. FDA and leadership roles within International Council for Harmonization, BIO and PhRMA. Plays a key role in shaping next-generation regulatory ecosystems, including structured data submissions, DHT, AI FHIR-enabled exchange, and digital collaboration platforms such as Accumulus and IRISS. Recognized for building high-performing global teams and driving enterprise-wide change, translating regulatory innovation into practical, scalable solutions that advance both organizational performance and industry standards.
